Pulmonary hypertension: Current diagnosis and treatment

Clinical Research in Cardiology

Volumn 96, Issue 8, 2007, Pages 527-541

  Rosenkranz, Stephan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Diagnosis; Endothelin receptor antagonists (ERAs); Phosphodiesterase type 5 (PDE5) inhibitors; Prostanoids; Pulmonary arterial hypertension (PAH); Pulmonary hypertension (PH)

Indexed keywords

AMBRISENTAN; AMLODIPINE; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ILOPROST; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

ANTICOAGULATION; BLOOD VESSEL REACTIVITY; CARDIOPULMONARY EXERCISE TEST; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EMBOLISM; EXERCISE TEST; GENETIC VARIABILITY; HEART CATHETERIZATION; HEART DISEASE; HEMODYNAMIC MONITORING; HUMAN; HYPOXEMIA; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG TRANSPLANTATION; NOMENCLATURE; OXYGEN THERAPY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR RESISTANCE;

HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROGNOSIS; PROSTAGLANDINS; PURINES; RECEPTORS, ENDOTHELIN; SULFONES;

EID: 34547100954     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0526-8     Document Type: Review

References (80)

1. Actelion Pharamceuticals (2006) data on file
2. American Thoracic Society (2002) ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 166:111-117
3. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, Mc Laughlin VV, American College of Chest Physicians (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (Suppl 1):35S-62S
4. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425-434
5. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galié N, on behalf of the STRIDE-2 Study Group (2006) Treatment of pulmonary arterial hypertension with the selective endothelin - A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049-2056
6. Barst RJ, Langleben D, Frost A, Horn EM; Oudiz R, Shapiro S, McLaughlin VV; Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441-447
7. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119-2125
8. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka M, Olschewski H, Gaine SP (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:40S-47S
9. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296-302
10. Bossone E, Alvelar E, Bach DS et al (2000) Diagnostic value of resting tricuspid regurgitation velocity and right ventricular ejection flow parameters parameters for the detection of exercise induced pulmonary arterial hypertension. Int J Card Imaging 16:429-436
11. Bossone E, Bodini BD, Mazza A, Allegra L (2005) Pulmonary arterial hypertension: the key role of echocardiography. Chest 127:1836-1843
12. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF (1999) Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 33:1662-1666
13. Channick RN, Simmoneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized, placebo-controlled study. Lancet 358:1119-1123
14. Chaouat A, Bugnet A-S, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189-194
15. Cremers B, Kjelström B, Südkamp M, Böhm M (2002) Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension. Am J Med 112:428-430
16. Currie PJ, Seward JB, Chan KL (1985) Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol 6:750-756
17. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349
18. Denton C, Cailes J, Phillips G, Wells A, Black C, Du Bois M (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239-243
19. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655-31665
20. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313-1321
21. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Resp Crit Care Med 174:1034-1041
22. Galié N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496-1502
23. Galié N, Seeger W, Naeije R, Simmoneau G, Rubin RJ (2004a) Comparative analysis of clinical trials and evidence- based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):S81-S88
24. Galié N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T et al (2004b) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. ESC Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25:2243-2278
25. Galié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simmoneau G, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
26. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A et al (2003) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139-1141
27. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360:895-900
28. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515-522
29. Hertz MI, Taylor DO, Trulock EP et al (2002) The registry of the international society for heart and lung transplantation: nineteenth official report 2002. J Heart Lung Transplant 21:950-970
30. Höper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24:1007-1010
31. Höper MM, Markevych I, Spiekerkötter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858-863
32. Höper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E (2003) Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22:330-334
33. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004a) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):13S-24S
34. Humbert M, Sitbon O, Simonneau G (2004b) Treatment of pulmonary arterial arterial hypertension. N Engl J Med 351:1425-1436
35. Kaul S, Tei C, Hopkins JM, Shah PM (1984) Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 107:526-531
36. Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P (2004) Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):73S-80S
37. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2005) Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension. Chest 127:1647-1653
38. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90(6):677-680
39. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ (2007) Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115:59-66
40. Magnussen H, Geockenjan G, Kohler D, Matthys H, Morr H, Worth H et al (2001) Guidelines to long-term oxygen therapy. Pneumologie 55:454-464
41. Masuyama T, Kodama K, Kitabatake A, Sato H, Nanto S, Inoue M (1986) Continuous- wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation 74:484-492
42. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE; American College of Chest Physicians (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence- based clinical practice guidelines. Chest 126(Suppl 1):14S-34S
43. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S; Treprostinil Study Group (2003) Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293-299
44. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417-1431
45. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Resp Crit Care Med 174:1257-1263
46. McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477-1482
47. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galié N, Rainisio M, Simonneau G, Rubin RJ (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244-249
48. McQuillan BM, Picard MH, Leavitt M, Weymann AE (2001) Clinical correlates and reference intervals for pulmonary artery systolic pressures among echocardiographically normal subjects. Circulation 104:2797-2802
49. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer J, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FFJ, Wilkens H, Katus HA, Olschewski H, Grünig E (2006) Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114:1482-1489
50. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403
51. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487-492
52. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865-870
53. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB; National Heart, Lung and Blood Institute/ Office of Rare Diseases (2004) Pulmonary arterial hypertension: future directions. Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 109:2947-2952
54. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G (2004) Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43(Suppl S12):33S-39S
55. nd Edition. Lippincott Williams & Wilkins, Philadelphia, pp 215-222
56. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Höper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435-443
57. Olschewski H, Ghofrani HA, Walmrath D, Schermuly RT, Temmesfeld- Wollbrück B, Grimminger F et al (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600-607
58. Olschewski H, Höper MM, Borst MM, Ewert R, Grünig E, Kleber F-X, Kopp B, Opitz C, Reichenberger F, Schmeisser A, Schranz D, Schulze-Neick I, Wilkens H, Winkler J, Worth H (2007) Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Leitlinien der Deutschen Gesellschaft für Pneumologie, der Deutschen Gesellschaft für Kardiologie und der Deutschen Gesellschaft für Pädiatrische Kardiologie. Clin Res Cardiol (in press)
59. Olschewski H, Simmoneau G, Galié N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Höper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study Group (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322-329
60. Ommen SR, Nishimura RA, Hurrell DG, Klarich KW (2000) Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc 75:24-29
61. Oudiz RJ (2005) The role of exercise testing in the management of pulmonary arterial hypertension. Sem Respir Crit Care Med 26:379-384
62. Pengo V, Lensing A, Prins M, Marchiori A, Davidson B, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257-2264
63. Penning S, Robinson K, Major C, Garite T (2001) A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol 184:1568-1570
64. Raymond RJ, Hinderliter AL, Willis PW et al (2002) Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39:1214-1219
65. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81
66. Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151-158
67. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 139:871-873
68. Rubin LJ, Badesh DB, Barst RJ, Galié N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simmonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903
69. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, Palomar A, Gomez A (1998) Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. J Am Coll Cardiol 32:297-304
70. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43:1149-1153
71. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE (2002) Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166:314-322
72. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ; Treprostinil Study Group (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804
73. Simonneau G, Galié N, Rubin L, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl 1): 5S-12S
74. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simmoneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105-3111
75. Tei C, Dujardin KS, Hodge DO et al (1996) Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9:838-847
76. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzynska L (2003) Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844-848
77. Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R (2002) Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary exercise testing. Circulation 106:319-324
78. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218-1222
79. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB (1998) Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81:1157-1161
80. Zahn R, Zeymer U, Scheidt T, Mark B, Layer G, Senges J (2006) An unusual cause of dyspnea and pulmonary hypertension in a patient with a symptom history of 20 years - "Just do it again". Clin Res Cardiol 95:68-71